vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink

MT Newswires Live07-27

vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink vTv Therapeutics (VTVT) said late Friday the US Food and Drug Administration has placed a "clinical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454137303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-27 05:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454137303","market":"fut","top_or_hot":-1,"title":"vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink","media":"MT Newswires Live","content":"<div>\n<p>vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink vTv Therapeutics (VTVT) said late Friday the US Food and Drug Administration has placed a \"clinical ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nvTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-27 05:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink vTv Therapeutics (VTVT) said late Friday the US Food and Drug Administration has placed a \"clinical ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTVT","symbol_name":"vTv Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2454137303","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454137303","pubTimestamp":1722027887,"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink vTv","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTVT":"vTv Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"vTv Therapeutics针对1型糖尿病的Cadisegliatin项目被临床搁置；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":1},"content_text":"vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink vTv Therapeutics (VTVT) said late Friday the US Food and Drug Administration has placed a \"clinical hold\" on its cadisegliatin clinical program, including an ongoing CATT1 phase 3 trial in type 1 diabetes.The clinical hold was based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion study of cadisegliatin that could not be resolved by standard mass spectroscopy, the late-stage drugmaker said.The FDA requires a single in vitro study to characterize this signal before the program can resume, vTv said, adding that no patient had been dosed in CATT1 at the time of the hold, and past studies did not reveal any clinically concerning safety issues.\"We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible,\" said CEO Paul Sekhri. Cadisegliatin has been well-tolerated in over 500 subjects to date with up to six months of treatment.vTv shares tumbled about 43% in extended trading.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454137303"}